Drug intelligence / Profile preview

Bugushengsui granule

Development stage: Unknown
Lead developer: 中国中医科学院望京医院
Administration: Oral

Overview

Bugushengsui granule is a Traditional Chinese Medicine (TCM) formulation developed by Wangjing Hospital of the China Academy of Chinese Medical Sciences for the treatment of primary osteoporosis. The preparation is based on traditional principles of tonifying the kidney and essence to strengthen the skeletal system. It has been evaluated in randomized clinical trials in China, specifically comparing its efficacy and safety against calcitriol soft capsules in adult patients. The granule formulation is intended to improve bone mineral density (BMD), alleviate bone pain, and improve the quality of life for patients suffering from age-related or postmenopausal bone loss.

Other names: Bugushengsui recipeBugushengsui granules

Beyond the preview

Go deeper on Bugushengsui granule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bugushengsui granule.

Explore the full profile